What Vida Ventures does

Vida Ventures is a bicoastal life sciences venture capital firm founded in 2018 by scientists, physicians, entrepreneurs, and investors, with a stated mission of transforming biomedical innovations into therapies. The firm invests in and creates biotechnology companies across therapeutic areas including oncology, immunology, genetic medicines, rare diseases, neurodegeneration, and pulmonary disease, operating flexibly across stages from de novo start-ups to commercial-stage enterprises through a company-creation model co-executed with Two River within the Bellco Health ecosystem.

The firm manages approximately $1.8 billion across three fund vehicles: Vida I ($295M, 2018), Vida II ($600M, 2019), and Vida III ($825M, 2021). Its 25-plus portfolio companies include high-profile de novo builds such as Aktis Oncology (radiopharmaceuticals), Candid Therapeutics (T-cell engagers, sold to UCB for up to $2.2B), Allogene Therapeutics (co-founded; CAR-T), Capstan Therapeutics (in vivo CAR-T, acquired by AbbVie), and Halda Therapeutics (RIPTACs, acquired by J&J). The firm also participates in syndicates for growth-stage rounds (SonoThera, Adcendo, Poplar). Strategic value-add derives from a deep scientific bench — including Scientific Advisory Board members drawn from National Academy-level academic institutions — and direct operational involvement by leadership including Arie Belldegrun M.D. (founder of Kite Pharma, sold to Gilead for $12B), Fred Cohen M.D./D.Phil. (ex-TPG Bio, UCSF), Helen S. Kim M.B.A. (ex-Kite Pharma EVP), and other senior operators.

Vida Ventures generates revenue through the standard venture capital model of management fees on assets under management (recurring) plus performance-based carried interest from successful portfolio company exits and IPOs. Distribution is via private fund structures to institutional limited partners. Operational footprint comprises headquarters in Los Angeles, with investment offices in Boston and New York and a finance/accounting office in Fort Worth. The firm uses a fellowship program, corporate website, social media, and selective industry-conference presence (e.g., J.P. Morgan Healthcare Conference) for visibility and talent pipeline development.

Name

Vida Ventures

Legal name

Vida Ventures, LLC

Website

http://vidaventures.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Vida Ventures is a bicoastal life sciences venture capital firm founded in 2018 managing approximately $1.8 billion across three funds, investing in and creating biotechnology companies developing therapeutics in oncology, immunology, genetic medicine, rare disease, and pulmonary disease.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Venture Debt Providers (FSANAAAL)

Keywords

• Life sciences venture capital
• Biotechnology investment
• Venture capital funds
• Biotech company creation
• Therapeutics equity financing

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Management Fees: Venture capital firms typically charge management fees on assets under management
2. Carried Interest: Performance-based carried interest from successful portfolio company exits

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Vida Ventures is a life sciences venture capital firm that invests in and supports biotechnology companies across stages and therapeutic areas. The firm manages approximately $1.8 billion across three funds (Vida I, Vida II, Vida III) and provides capital, strategic guidance, operational expertise, and company-creation services to portfolio companies developing therapeutics in oncology, immunology, genetic medicines, rare diseases, and neurodegenerative disorders. The firm also operates a fellowship program and maintains an investor portal for limited partners.

Product overview

Vida Ventures is a next-generation life sciences venture capital firm that invests in and supports biotechnology companies across various stages of development. The firm does not offer proprietary technology products or platforms; instead, it provides investment capital, strategic guidance, and operational expertise to its portfolio companies. Vida Ventures manages approximately $1.8 billion across multiple funds and maintains a diverse portfolio of biotechnology companies focused on therapeutics development in areas including oncology, immunology, genetic medicines, rare diseases, and neurological disorders. The firm also offers a fellowship program and maintains an investor portal for limited partners.

Differentiator

Problem solved

Functional benefit

Products and services

• Vida I Fund Vida Ventures' first institutional life sciences venture capital fund, providing equity capital to early- and growth-stage biotechnology companies developing transformative therapeutics. Aimed at institutional limited partners.
• Vida II Fund Second-generation life sciences venture capital fund expanding Vida's deployable capital across stages and therapeutic areas. Aimed at institutional limited partners.
• Vida III Fund Third life sciences venture capital fund supporting later-stage and company-creation activities within Vida Ventures' portfolio strategy. Aimed at institutional limited partners.
• Vida Ventures Fellowship Program Industry fellowship program providing training and exposure to venture capital and biotechnology company building for emerging scientists and physicians. Aimed at prospective biotech operators and investors.
• Limited Partner Investor Portal Secure investor portal (eFront cloud-based) that provides limited partners with reporting, capital account information, and fund documentation access. Aimed at Vida Ventures' institutional limited partners.

Quantifiable outcome

• 4 M&A transactions completed in 2025 with $2.2B+ in value realization
• +1 more outcomes

Named customers8 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Two RiverflagshipStrategic or Co-development Partner · 4 May 2026Two River and Vida Ventures are both part of the Bellco Health ecosystem and played central roles in founding and developing Candid Therapeutics through the merger of TRC 2004 and Vignette Bio

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• ARCH Venture Partners: One of the largest and most established US life sciences venture capital firms, focused on early-stage biotech and company creation across therapeutics and platform technologies. Direct peer to Vida given similar stage-agnostic, company-creation-driven investment model in US biotech.
• Flagship Pioneering: Biotech-focused venture firm that originates and grows platform companies internally (e.g., Moderna). Most comparable peer to Vida on the company-creation model, with significantly larger AUM but a parallel orientation toward building biotech platforms from inception.
• MPM BioImpact: US life sciences venture firm investing across oncology and biomedical innovation. Direct peer, including via co-investment with Vida in Aktis Oncology; comparable in stage, therapeutic focus, and company-creation approach.
• The Column Group: Scientifically driven life sciences venture capital firm that has employed Helen Kim, a senior MD at Vida. Direct peer given shared model of scientist-led, early-stage therapeutics investing and similar AUM scale.
• Versant Ventures: Healthcare-focused venture firm with strong company-creation track record (e.g., Inception Sciences). Comparable peer to Vida across stage range, therapeutic breadth, and biotech incubation strategy.
• Atlas Venture: Early-stage biotech venture firm that builds and funds companies from inception. Direct peer to Vida on a stage-agnostic, founder-build approach in US/EU biotech therapeutics.
• OrbiMed: One of the largest dedicated healthcare investment firms globally, spanning venture, growth, and credit. Comparable peer in therapeutic breadth and life sciences focus, though larger and broader in mandate.
• RA Capital Management: Healthcare-focused investment firm that combines public and private biotech investing, and is a frequent co-investor with Vida (e.g., SonoThera Series B). Direct peer in life sciences deal flow and company-building.
• Baker Bros. Advisors: Biotech-focused investment adviser with a long history of concentrated life sciences positions. Comparable peer on therapeutic focus and conviction-driven investing model, though typically operates at much larger scale.
• 5AM Ventures: Early-stage life sciences venture firm focused on building biotech companies from platform technologies. Comparable peer to Vida in stage, therapeutic breadth, and company-creation orientation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Vida_Ventures
• LinkedInlinkedin.com/company/vida-ventures-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments67 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vida Ventures